Cardiac screening investigations in adult-onset progressive external ophthalmoplegia patients

Authors

  • Gerald Pfeffer MD, CM,

    1. Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
    2. Clinician Investigator Program, University of British Columbia, Vancouver, British Columbia, Canada
    Search for more papers by this author
  • Michelle M. Mezei MD, CM

    Corresponding author
    1. Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
    2. Adult Metabolic Disease Clinic, University of British Columbia, Fourth Floor, GLDHCC, 2775 Laurel Street, Vancouver, British Columbia V5Z 1M9, Canada
    • Division of Neurology, University of British Columbia, Vancouver, British Columbia, Canada
    Search for more papers by this author

Abstract

Introduction: Patients with mitochondrial myopathies may develop cardiac complications such as cardiomyopathy and/or cardiac conduction defects. To identify these potentially life-threatening and treatable conditions, it is common practice to screen patients intermittently with electrocardiography and echocardiography. The optimal time interval for such screening investigations is unknown. We developed this study to review our screening results in adult-onset patients with progressive external ophthalmoplegia (PEO). Methods: This study was a retrospective review of PEO patients with 5 years or more of cardiac screening investigations who did not have any cardiac symptoms. Results: Fifteen patients were included, and cardiomyopathy was identified on screening echocardiogram in 1 patient. Four patients had other abnormalities identified, which were unrelated to their mitochondrial myopathy. Conclusions: Only 1 patient in 15 developed cardiac complications related to mitochondrial disease during 5 years of follow-up. We suggest that a screening interval of 3–5 years is probably appropriate for adult-onset PEO patients who do not have cardiac symptoms. Muscle Nerve 60: 608–611, 2012

Ancillary